VX-770 (Ivacaftor) is a first-in-class potentiator of CFTR, which targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively. VX-770 (Ivacaftor) inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. VX-770 (Ivacaftor) is the first potent and orally available CFTR potentiator to enter human clinical trials. It showed that VX-770 (Ivacaftor) was associated with within-subject improvements in CFTR and lung function. These findings provide support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
 |
Source | Physiology University of Toronto (2015). Figure 21. VX-770 (AbMole BioScience, Cedarlane, Burlington, Canada) |
| Method | CFTR potentiation | |
| Cell Lines | C57BL/6 WT mice | |
| Concentrations | 100nM | |
| Incubation Time | 30 min | |
| Results | Since CFTR(inh)-172 results in the inhibition of proper CFTR gating leading to an elevated myogenic vasoconstriction, treatment with potentiator VX-770 might also potentiate CFTR’s capacity to transport S1P and, therefore, compensate for part of the lost CFTR. |
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | Iodide Flux Assay—Proteoliposomes were reconstituted in the presence of 75 mM KI. The external iodide was exchanged for 75 mM potassium glutamate by gel filtration chromatography. External iodide concentrations were monitored continuously using an iodide-selective electrode (Lazar Research Laboratories, Los Angeles, CA) interfaced to the Digidata 1320A data acquisi ion system and controlled by Clampex 8 software (Axon Instruments, Sunnyvale, CA), as described previously (17, 18). |
| Concentrations | 10 μM |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 392.49 |
| Formula | C24H28N2O3 |
| CAS Number | 873054-44-5 |
| Solubility (25°C) | DMSO 65 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related CFTR Products |
|---|
| GLPG2737
GLPG2737 is a novel potent Type 2 corrector of CFTR. GLPG2737 showed high permeability both in MDCKII-MDRI and Caco-2 cells, with low efflux allowing an elevated absorbed fraction FaxFg and a dose proportional increase in exposure in rat from a dose of 5 to 300 mg/kg, despite a low aqueous thermodynamic solubility. |
| UCCF-853
UCCF-853 is a cystic fibrosis transmembrane regulatory protein (CFTR) modulator. |
| (R)-Posenacaftor sodium
(R)-Posenacaftor sodium is the R-enantiomer of Posenacaftor and a cystic fibrosis transmembrane regulatory protein (CFTR) modulator that corrects the folding and transport of CFTR proteins.Posenacaftor is used in studies related to cystic fibrosis (CF). |
| (R)-Olacaftor
(R)-Olacaftor is a cystic fibrosis transmembrane regulator (CFTR) modulator that can be used in cystic fibrosis (CF) related studies. |
| CFTR corrector 9
CFTR corrector 9 is a cystic fibrosis transmembrane conductance regulator protein (CFTR) modulator for cystic fibrosis (CF) and other CFTR-related diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
